pentadecapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-01 and is reviewed periodically as new material appears.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
== Side effects == Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear. A new wave of fentanyl analogues and associated deaths began in around 2014 in the US, and have continued to grow in prevalence; especially since 2016 these drugs have been responsible for hundreds of overdose deaths every week.
Sanlúcar's name may have derived from the Arab šurūq (Arabic: شروق), the Arabic name for the Levant wind called sirocco or jaloque. According to the National Statistics Institute of Spain, the Sanlúcar toponym does not exist. However, there is historical mention of Brother Alfonso Sanlúcar de Barrameda, a Franciscan who was bishop of the Canaries-Rubicon in the period 1404–1417, and Fray Juan de Sanlúcar, a Franciscan who served in the same office from 1470–1474. As for the name Barrameda, it is unique to people born in the Canary Islands, according to census data from 1 January 2006. The historical relations between the House of Medina Sidonia, Sanlúcar, and the Canaries may explain the presence of these surnames in the Canaries. Barrameda was derived from bar-am-ma'ida, an Arabic phrase for "water well of the plateau".
British Post Office scandal: Court documents reveal that Fujitsu, the company at the centre of the Post Office scandal, won a £184m contract by the Foreign and Commonwealth Office in 2021, despite concerns the system it was offering was "unfit for purpose". Court documents show that former prime minister Sir Tony Blair was warned the Horizon IT system could be "possibly unreliable" before it was rolled out, and raised concerns about it, but gave it the green light after receiving reassurance from others, including his Secretary of State for Trade and Industry Peter Mandelson. 13 January – Yvonne Tracey, a former deputy postmistress from New Malden, south London, announces her intention to stand in the Parliamentary constituency of Kingston and Surbiton, Sir Ed Davey's seat, at the next general election. 14 January – Foreign Secretary David Cameron tells the BBC that military action was taken against Houthi rebels because the strikes were needed after months of attacks against cargo ships, and that the UK is "prepared to back our words with actions". 15 January – Sunak tells Parliament that air strikes against Houthi targets were meant as a "limited, single action" but that the UK "will not hesitate to protect our security, our people and our interests where required". James Stockan announces he is stepping down from the post of leader of Orkney Islands Council, as well as relinquishing his council seat, after six years in the role.
Although a previous publication reported traces of the chemical 24-isopropyl cholestane in ancient rocks dating to 1,800 million years ago, recent research using a much more accurately dated rock series has revealed that these biomarkers only appear before the end of the Marinoan glaciation approximately 635 million years ago, and that "Biomarker analysis has yet to reveal any convincing evidence for ancient sponges pre-dating the first globally extensive Neoproterozoic glacial episode (the Sturtian, ~713 million years ago in Oman)". While it has been argued that this 'sponge biomarker' could have originated from marine algae, recent research suggests that the algae's ability to produce this biomarker evolved only in the Carboniferous; as such, the biomarker remains strongly supportive of the presence of demosponges in the Cryogenian. Archaeocyathids, which some classify as a type of coralline sponge, are very common fossils in rocks from the Early Cambrian about 530 to 520 million years ago, but apparently died out by the end of the Cambrian 490 million years ago. It has been suggested that they were produced by: sponges; cnidarians; algae; foraminiferans; a completely separate phylum of animals, Archaeocyatha; or even a completely separate kingdom of life, labeled Archaeata or Inferibionta. Since the 1990s, archaeocyathids have been regarded as a distinctive group of sponges.
Sources: en.wikipedia.org
24 September – Scientists report the successful return of samples from NASA's OSIRIS-REx mission to the asteroid 101955 Bennu. Shortly after the sample container was retrieved and transferred to an "airtight chamber at the Johnson Space Center in Houston, Texas", the lid on the container was opened. Scientists commented that they "found black dust and debris on the avionics deck of the OSIRIS-REx science canister" on the initial opening. Later study was planned. A news conference on the asteroid sample is scheduled for 11 October 2023. 25 September A study on Pangaea Ultima finds that the hypothetical supercontinent will make Earth uninhabitable to most life forms in 250 million years, due to extreme temperatures and radiation. Biologists report the discovery of a ninth species of pangolin, a mammal which is covered with large, protective keratin scales. 26 September – Work begins on the seventh and final primary mirror of the Giant Magellan Telescope, which is expected to provide quadruple the image resolution of previous observatories when completed.
=== Elsewhere === Generally, the firmer styles of tofu are used for kebabs, mock meats, and dishes requiring a consistency that holds together, while the softer styles can be used for desserts, soups, shakes, and sauces. Some people enjoy tofu made and prepared with chocolate and making it into pies and mousse along with other tofu desserts. This came about due to vegans and vegetarians avoiding the usage of items such as milk and eggs. Firm Western tofu types can be barbecued since they hold together on a barbecue grill. These types are usually marinated overnight as the marinade does not easily penetrate the entire block of tofu. (Techniques to increase the penetration of marinades include stabbing repeatedly with a fork or pressing out the initial water content either by hand or with a tofu press prior to marinating. Before pressing the tofu, it is sometimes frozen and thawed in order of creating a more porous texture, often compared to a sponge. This texture does not only help release the initial water content, but also allows for an altered mouthfeel and more absorbent structure. Typically, the tofu is frozen and thawed once, although some culinary experts recommend executing this technique twice for a stronger effect.) Grated firm Western tofu is sometimes used in conjunction with textured vegetable protein (TVP) as a meat substitute. Softer tofus are sometimes used as a dairy-free or low-calorie filler. Silken tofu may be used to replace cheese in certain dishes, such as lasagna.
== Other related disorders == When sIBM was originally described, the major feature noted was muscle inflammation. Two other disorders were also known to display muscle inflammation, and sIBM was classified along with them. They are dermatomyositis (DM) and polymyositis (PM) and all three illnesses were called idiopathic (of unknown origin) myositis or inflammatory myopathies. It appears that sIBM and polymyositis share some features, especially the initial sequence of immune system activation, however, polymyositis comes on over weeks or months, does not display the subsequent muscle degeneration and protein abnormalities as seen in IBM, and as well, polymyositis tends to respond well to treatments, IBM does not. IBM is often confused with (misdiagnosed as) polymyositis. Polymyositis that does not respond to treatment is likely IBM. Dermatomyositis shares a number of similar physical symptoms and histopathological traits as polymyositis, but exhibits a skin rash not seen in polymyositis or sIBM. It may have different root causes unrelated to either polymyositis or sIBM. Mutations in valosin-containing protein (VCP) cause multisystem proteinopathy (MSP), which can present (among others) as a rare form of inclusion body myopathy.
==== Global Compact for Migration ==== On 8 January 2023, Foreign Minister Mauro Vieira announced Brazil rejoined the Global Compact for Migration from which the Bolsonaro government withdrew on 9 January 2019 The UNHCR welcomed the decision stating that ensures "the people's rights and the means so that migrants and refugees can contribute positively to the host countries". According to the Foreign Ministry, the party's mutual benefits of the pact also reflect on the "Brazilian government's commitment to the protection and promotion of the rights of more than 4 million Brazilians living abroad".
=== Spinal muscular atrophy === In 2004, development of an antisense therapy for spinal muscular atrophy began. Over the following years, an antisense oligonucleotide later named nusinersen was developed by Ionis Pharmaceuticals under a licensing agreement with Biogen. In December 2016, nusinersen received regulatory approval from FDA and soon after, from other regulatory agencies worldwide.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.